Culturally adapted therapy for suicidal thoughts in first episode psychosis

Culturally Adapted Psychosocial Intervention for Suicidal Ideation in Individuals With First Episode Psychosis: A Feasibility Randomised Controlled Trial

Not applicable Interventional Pakistan Institute of Living and Learning · NCT05728138

This study is testing a new type of therapy designed to help people experiencing suicidal thoughts during their first episode of psychosis, particularly in countries with limited mental health resources.

Quick facts

PhaseNot applicable
Study typeInterventional
Enrollment80 (estimated)
Ages18 Years and up
SexAll
SponsorPakistan Institute of Living and Learning Academic / other
Locations1 site (Karachi, Sindh)
Trial IDNCT05728138 on ClinicalTrials.gov

What this trial studies

This trial evaluates the feasibility and acceptability of culturally adapted Cognitive Behavioral Therapy for Psychosis (CaCBTp) and a brief psychological intervention for self-harm (CMAP Plus) in individuals experiencing suicidal ideation during their first episode of psychosis. The study aims to address the significant treatment gap in low- and middle-income countries like Pakistan, where mental health resources are limited. By focusing on culturally relevant approaches, the trial seeks to provide effective psychosocial interventions for a vulnerable population. Participants will be assessed for their eligibility based on specific mental health criteria and will receive tailored therapeutic support.

Who should consider this trial

Good fit: Ideal candidates include individuals aged 18 and above diagnosed with schizophrenia or schizoaffective disorder who exhibit mild suicidal thoughts.

Not a fit: Patients with severe suicidal ideation or those with significant comorbid illnesses or organic brain diseases may not benefit from this intervention.

Why it matters

Potential benefit: If successful, this intervention could significantly reduce suicidal ideation and improve mental health outcomes for individuals experiencing first episode psychosis.

How similar studies have performed: While there is limited research on culturally adapted therapies in low-income settings, similar approaches in high-income countries have shown promise in improving mental health outcomes.

Eligibility criteria

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Individuals diagnosed with, Schizophrenia or Schizoaffective disorder according to DSM-V, confirmed by treating consultant.
* Age 18 and above years able to understand written and spoken Urdu.
* A score of 1 (Mild- Frequent thoughts of being better off dead, or occasional thoughts of suicide.) on the Calgary depression Scale item 8 (Suicide) "Have you felt that life wasn't worth living? Did you ever feel like ending it all? What did you think you might do? Did you actually try?"
* Individuals with a score of 3 or more on any of the positive symptoms on the Positive and Negative Syndrome Scale (PANSS) (e.g., delusions, hallucination).

Exclusion Criteria:

* Any evidence of organic brain disease, clinically significant comorbid illness or learning disability. Participants deemed actively suicidal by their designated health professional.
* Those scoring \>1 on Calgary depression Scale will be excluded and be referred to a psychiatric service.

Where this trial is running

Karachi, Sindh

Study contacts

How to participate

  1. Review the eligibility criteria above with your treating physician.
  2. Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
  3. Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions Self Harm, First Episode PsychosisSelf-harm, First Episode Psychosis, adaptation, problem-solving.
Last reviewed 2026-06-13 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.